BIOMAT Database Logo BIOMAT Database Logo

Stimulation of antiviral activities of interferon by a liver extract preparation. 1997

S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
Sanwa Kagaku Kenkyusho Co., Ltd., Mie, Japan.

The liver extract preparation Adelavin9 (referred to as EXT-FAD hereinafter) is a combination product that consists of hog liver extract and flavin-adenine dinucleotide (FAD). EXT-FAD has been reported to improve the histology of chronic liver injury and is widely used in Japan. Interferon (IFN) has been used to treat viral hepatitis. In this study, the action of EXT-FAD on the antiviral activity of IFN was examined using experimental models of viral infection in vitro and in vivo. EXT-FAD significantly enhanced the 2',5'-oligoadenylate synthetase (2-5AS) activity in human peripheral blood mononuclear cells (PBMC) treated with human IFN-alpha-2a. EXT-FAD is likely to affect the late phase of IFN action to produce the antiviral activity. Combination of IFN-alpha-2a with EXT-FAD produced a synergistic inhibitory effect against herpes simplex virus type-1 (HSV-1) in vitro. The effect of EXT-FAD in combination with IFN-alpha-2a against influenza virus type A (Fluv A) was also examined and a similar effect to that found in the anti-HSV-1 assay was observed. In addition, administration of EXT-FAD to mice infected with HSV-1 significantly prolonged the mean survival periods. The intracellular redox state plays a role in inhibiting virus replication. EXT-FAD was found to increase the intracellular glutathione (GSH) level. EXT-FAD also enhanced the nitric oxide synthase (NOS) activity, which plays a role in antiviral effects. This result indicate that the effect of EXT-FAD on the antiviral activity of IFN is partially related to increased intracellular GSH levels and NOS activation.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009696 Nucleic Acids High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages. Nucleic Acid,Acid, Nucleic,Acids, Nucleic
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D010948 Viral Plaque Assay Method for measuring viral infectivity and multiplication in CULTURED CELLS. Clear lysed areas or plaques develop as the VIRAL PARTICLES are released from the infected cells during incubation. With some VIRUSES, the cells are killed by a cytopathic effect; with others, the infected cells are not killed but can be detected by their hemadsorptive ability. Sometimes the plaque cells contain VIRAL ANTIGENS which can be measured by IMMUNOFLUORESCENCE. Bacteriophage Plaque Assay,Assay, Bacteriophage Plaque,Assay, Viral Plaque,Assays, Bacteriophage Plaque,Assays, Viral Plaque,Bacteriophage Plaque Assays,Plaque Assay, Bacteriophage,Plaque Assay, Viral,Plaque Assays, Bacteriophage,Plaque Assays, Viral,Viral Plaque Assays
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell

Related Publications

S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[An antiviral preparation interferon].
March 1961, Antibiotiki,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[Stimulation by isoprinosine of the antiviral effect of interferon].
February 1977, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[Human interferon: molecular mechanisms of antiviral activities].
September 1995, Nihon rinsho. Japanese journal of clinical medicine,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[Antiviral activities of interferon and PML pathway].
February 2008, Virologie (Montrouge, France),
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities.
July 1991, Virology,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
Inhibition of the antiviral action of interferon by tick salivary gland extract.
April 2000, Parasite immunology,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
Non-antiviral activities of interferon are not controlled by chromosome 21.
July 1975, Nature,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[Human interferon: molecular mechanism of its antiviral activities].
July 2004, Nihon rinsho. Japanese journal of clinical medicine,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
[The interferon-induced and antiviral activities of dipeptides].
January 2010, Voprosy virusologii,
S Yokochi, and Y Ishiwata, and H Saito, and H Ebinuma, and M Tsuchiya, and H Ishii
Different antiviral spectra of human macrophage interferon activities.
January 1983, Nature,
Copied contents to your clipboard!